ConductScreen
Automated Morphological Phenotyping of Developmental Neurotoxicity in Human Neural Organoids
A combinatorial in vitro/in silico NAM for quantifying how prenatal substance exposure alters neurodevelopmental morphology. No animals required.
1,407
Images Analyzed
64
Organoids Tracked
4
Cell Lines Compared
23/27
Significant Differences
Four Analysis Modules
A multi-modal combinatorial NAM from single-image morphology to electrophysiology and longitudinal dynamics.
Morphology Module
Operational2D Morphology from Brightfield Microscopy
Automated segmentation and feature extraction from standard brightfield images. No fluorescent labels required.
- 16 features + 3 QC metrics per image
- 9 morphology, 3 intensity, 4 texture features
- Deterministic pipeline at 130 ms/image
- Cross-lab reproducibility validated
Electrophysiology Module
Phase 2MEA/Calcium Electrophysiology
Multi-electrode array and calcium imaging analysis to correlate morphological phenotypes with functional network activity changes from substance exposure.
- Burst rate and spike frequency
- Network synchrony metrics
- Connectivity mapping
- Functional-morphological correlation
Boundary Module
Phase 23D Confocal Neurite Topology
Skeletonization and graph-based analysis of neurite morphology from 3D confocal stacks.
- Skeleton total length and branch length
- Branch point and terminal tip counts
- Topological complexity (Betti numbers)
- Sholl analysis intersection profile
Temporal Module
PrototypeTime-Series Growth Dynamics
Longitudinal tracking of organoid growth, shape evolution, and phenotypic divergence over culture days.
- Growth curves with exponential/logistic fits
- Doubling time estimation
- Trajectory clustering
- Dose-response morphological curves
Key Finding
Our automated pipeline detects statistically significant morphological differences between wildtype and disease-model organoids across 23 of 27 feature-clone comparisons (BH-FDR q < 0.05, per-organoid aggregated N=16 per group), achieving an 85.2% discrimination rate with effect sizes |r| = 0.46–1.0.
Critically, the features that distinguish disease from wildtype — area, boundary integrity, tissue texture, and intensity heterogeneity — are the same endpoints reported as affected by prenatal substance exposure across 20+ published studies spanning 9 substance classes. This establishes both analytical validity and biological plausibility for the target context of use.
Beyond Software: A Complete Testing System
ConductScreen is the intelligence layer of a complete, integrated developmental neurotoxicity testing system.
Culture Chip
Hardware
Standard Protocol
Media kit
Any Microscope
Brightfield
ConductScreen
Analysis
Phase 3 delivers the full system. No organoid expertise needed.
Learn more about Culture ChipCulture Chip builds on ConductScience's existing microfluidic chip manufacturing platform — organ-on-a-chip devices already in production for labs worldwide.
Regulatory Readiness
ConductScreen is designed for regulatory qualification under OECD Test Guideline 426. Explore our evidence:
NAM-vs-Animal Concordance
See how each ConductScreen feature maps to OECD TG 426 animal endpoints, with published evidence linking them.
View DashboardContext of Use Explorer
Interactive walkthrough of the regulatory pathway: what TG 426 requires, how we address it, and our validation roadmap.
Explore PathwayBuilt on Real, Published Data
All analysis is performed on data from Zenodo 10301912 (Schröter et al., Scientific Data 2024) — 1,407 brightfield microscopy images from 64 organoids across 4 iPSC-derived cell lines (1 wildtype + 3 disease models).
No synthetic or simulated data. Every result shown on this site is derived from real experimental images.
NIH Complement-ARIE Reduction to Practice Challenge — Phase 1
A combinatorial in vitro/in silico NAM for automated morphological phenotyping of developmental neurotoxicity in human neural organoids